Archives

  • 2019-06
  • 2018-12
  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-08
  • 2021-03
  • Sorafenib br E ectiveness of the HPV vaccine br

    2019-11-12


    4.1.2. Effectiveness of the HPV vaccine
    Many participants perceived that they lacked adequate knowledge about HPV and the HPV vaccination. Without adequate information, participants expressed uncertainty about the effectiveness of the HPV vaccine. Even participants who reported regular health care access suggested that they did not know enough about HPV and cervical cancer and wondered if the vaccine actually prevented HPV. Although many participants chose to vaccinate their children, some participants decided against HPV Sorafenib because they lacked comprehensive information about the vaccine and HPV-related cancers. According to a 38 year-old African American participant, “I just think it's very strange that everyone should be vaccinated against it … my son isn't getting it. My daughter won't get it either. My 10-year-old.” A 40 year-old Hispanic participant expressed her concern regarding the vaccine, “I'm doubtful. I heard about the vaccine - that it wasn't good to give it to them.”
    Many participants described a mistrust of the HPV vaccine based on their perception of it as a “new” vaccine. These participants described the vaccine as “really new.” According to a 38 year-old African American participant, “I think it's interesting how HPV is the new thing that everyone needs to be vaccinated against. I'm skeptical of it.” A 55 year-old African American participant described HPV as “just the newest boogeyman medical thing” deterring her from seeking the vaccination. Some participants described resisting the “pressure” they experienced from health care providers to receive the vaccination. These participants suggested that they did not know enough about the vaccine and could not be forced to accept it.
    4.2. Social norms: HPV, HPV vaccination, and cervical cancer
    4.2.1. Concerns regarding sexual behavior
    The majority of participants linked HPV and the HPV vaccine with sexual health and behavior. Most participants described HPV as “in-troduced or exacerbated by sexual activity” (age 54, white). According to a 38 year-old African American participant, “it strikes me as this way of protecting young girls who are having sex from this potential, sexual infection.” This relationship caused concern for some participants  Social Science & Medicine 232 (2019) 289–297
    because HPV is associated with sexual behavior. Participants described how influential others in their social networks impacted their vacci-nation decisions. A 47 year-old African American participant, who re-ported having health insurance and regular health care, described how the social implications of a positive HPV Sorafenib diagnosis motivated her to complete the HPV vaccination series, “the reputation of some of the girls from high school who had been around [sexually active] … I don't want to be that girl.”
    4.2.2. Gendered HPV vaccination
    While participants correctly linked the HPV vaccine with cervical cancer, they were unaware of other HPV-related cancers. Many parti-cipants did not know the current HPV vaccine recommendations for boys and young men. They shared their perception of the vaccine as “only for girls.” According to a 30 year-old African American partici-pant who reported having a daughter, “somewhere a few months ago, I found out that guys can get it … I don't know any in-depth informa-tion.” Gender played a unique role on knowledge about the HPV vac-cination. One 47 year-old African American parent said, “I don't think I have received an adequate amount [of information]. Probably because I don't have girls.” Other participants who reported regular access to reproductive health care agreed, “I don't have daughters and it doesn't apply to me” (66, Native American) and “I thought it was only for girls” (32, African American). r>